Trimetrexate

Also known as: 2,4-Quinazolinediamine, 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-, 5-Methyl-6-(3,4,5-trimethoxyanilinomethyl)quinazoline-2,4-diamine, 5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine, 5-Methyl-6-{[(3,4,5-triMethoxyphenyl)aMino]Methyl}quinazoline-2,4-diaMine, 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine, CI-898, Jb-11, NSC-249008, NSC249008, Trimetrexato, Trimetrexatum

Trimetrexate (CAS 52128-35-5) is a compound in the Organic Compounds category listed in the Jingsj chemical database. It has the molecular formula C19H23N5O3 and a molecular weight of 369.41800 g/mol. Key properties include a boiling point of 647ºC at 760mmHg, a density of 1.305g/cm3 and a flash point of 345.1ºC. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 52128-35-5
Jingsj CID: J-1974637-3
Molecular Formula: C₁₉H₂₃N₅O₃
Molecular Weight: 369.41800 g/mol
Category: Organic Compounds
Last updated: 8/21/2026

Request MSDS / TDS

No offers for this compound yet.

Request a quote

Physicochemical Properties

Boiling Point	647ºC at 760mmHg
Density	1.305g/cm3
Flash Point	345.1ºC
Exact Mass	369.18000
PSA	117.54000
LogP	3.97590
Storage Conditions	2-8℃

Activity & Biological Data

Additional Information	[1]. Allegra CJ, et al. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1987 Oct 15;317(16):978-85. [2]. Fulton B, et al. Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocystis carinii pneumonia. Drugs. 1995 Apr;49(4):563-76. [3]. Sattler FR, et al. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/031. J Infect Dis. 1994 Jul;170(1):165-72.

Additional Information

[1]. Allegra CJ, et al. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1987 Oct 15;317(16):978-85. [2]. Fulton B, et al. Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocystis carinii pneumonia. Drugs. 1995 Apr;49(4):563-76. [3]. Sattler FR, et al. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/031. J Infect Dis. 1994 Jul;170(1):165-72.

Customs & Trade Information

HS Code	2933990090
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Frequently Asked Questions

What is the CAS number of Trimetrexate?

The CAS number of Trimetrexate is 52128-35-5.

What are the molecular formula and molecular weight of Trimetrexate?

Trimetrexate has molecular formula C19H23N5O3 and molecular weight 369.41800 g/mol.

What are the upstream and downstream products of Trimetrexate?

For Trimetrexate, Upstream Products: Quinazoline, 3,4,5-Trimethoxyaniline.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "Trimetrexate (CAS 52128-35-5)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-1974637-3 (accessed 2026-11-09).

Data for reference only; verify product details with suppliers before purchase.